Gilad S. Gordon
Corporate Officer/Principal bei University of Colorado Health Sciences Center
Profil
Gilad S.
Gordon is currently an Assistant Professor at the University of Colorado Health Sciences Center.
He previously worked as a Principal at Eli Lilly & Co., Synergen, Inc., and as Acting Chief Medical Officer at Athenex, Inc. He also held positions as Vice President-Medical Affairs at FeRx, Inc., Chief Medical Officer at Prevacept Infection Control, Inc., and Chief Medical Officer at Inviragen, Inc. Prior to his industry experience, he earned a doctorate from Harvard Medical School, an MBA from the University of Washington, and an undergraduate degree from Harvard College.
Aktive Positionen von Gilad S. Gordon
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Colorado Health Sciences Center | Corporate Officer/Principal | 02.03.2010 |
Ehemalige bekannte Positionen von Gilad S. Gordon
| Unternehmen | Position | Ende |
|---|---|---|
| University of Indianapolis | Corporate Officer/Principal | 01.01.1992 |
Prevacept Infection Control, Inc.
 Prevacept Infection Control, Inc. Pharmaceuticals: MajorHealth Technology Prevacept Infection Control, Inc. develops and designs pharmaceutical products to eliminate microbial infections. The firm offers B-Lock, an anti-coagulant catheter lock solution with broad spectrum activity against bacterial and fungal microorganisms known to form bio-film structures in indwelling catheters. The company was founded by Krzysztof Appelt and Thomas I. Bradshaw in 2006 and is headquartered in Broomfield, CO. | Technik-/Wissenschafts-/F&E-Leiter | - |
Inviragen, Inc.
 Inviragen, Inc. BiotechnologyHealth Technology Inviragen, Inc. developed life-saving vaccine to protect against infectious diseases worldwide. The company was founded by Dan T. Stinchcomb and Jorge Osorio in November 2003 and was headquartered in Fort Collins, CO. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Synergen, Inc. | Portfolio Manager-Fixed Income | 02.03.2010 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von Gilad S. Gordon
| University of Washington | Masters Business Admin |
| Harvard College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 5 |
|---|---|
FeRx, Inc.
 FeRx, Inc. Medical SpecialtiesHealth Technology FeRx Inc. develops, manufactures, and distributes magnetic targeted carrier technology for the treatment of cancer. Its technology is used in therapeutic areas and provides technology platform for delivery of small molecules, radionuclides, biologics and genetic vectors. The company was registered in 1997 and is headquartered in San Diego, CA. | Health Technology |
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
| Synergen, Inc. | Utilities |
Inviragen, Inc.
Inviragen, Inc. BiotechnologyHealth Technology Inviragen, Inc. developed life-saving vaccine to protect against infectious diseases worldwide. The company was founded by Dan T. Stinchcomb and Jorge Osorio in November 2003 and was headquartered in Fort Collins, CO. | Health Technology |
Prevacept Infection Control, Inc.
Prevacept Infection Control, Inc. Pharmaceuticals: MajorHealth Technology Prevacept Infection Control, Inc. develops and designs pharmaceutical products to eliminate microbial infections. The firm offers B-Lock, an anti-coagulant catheter lock solution with broad spectrum activity against bacterial and fungal microorganisms known to form bio-film structures in indwelling catheters. The company was founded by Krzysztof Appelt and Thomas I. Bradshaw in 2006 and is headquartered in Broomfield, CO. | Health Technology |
